Phase 3 study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013)

Presented at the American Society of Clinical Oncology annual conference, researchers from Japan found doublet chemo with S-1 and cisplatin (CS) first-line chemo improved survival for advanced gastric cancer patients compared with CS alone. They also found the addition of docetaxel to CS did not improve survival for patients with untreated advanced gastric cancer.